Savara Inc (SVRA) Current Ratio
- Current ratio · latest quarter: Value 10.13×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 10.13× | Current assets / current liabilities. $178.32M ÷ $17.60M ≈ 10.13× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 178.32M USD | Assets, Current |
| Current obligations | 17.60M USD | Liabilities, Current |
| Cash and equivalents | 41.80M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 7.00M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $178.32M | $17.60M | $41.80M | (m) | (m) | (m) | $7.00M | $0.00 | 10.13× |
| 2026-03-31 | $209.26M | $15.54M | $38.79M | (m) | (m) | (m) | $4.50M | $0.00 | 13.47× |
| 2025-12-31 | $241.62M | $20.40M | $33.18M | (m) | (m) | (m) | $5.76M | (m) | 11.85× |
| 2025-09-30 | $128.20M | $16.76M | $16.28M | (m) | (m) | (m) | $4.14M | $0.00 | 7.65× |
| 2025-06-30 | $150.99M | $13.63M | $17.44M | (m) | (m) | (m) | $4.75M | $0.00 | 11.08× |
| 2025-03-31 | $177.44M | $11.90M | $19.56M | (m) | (m) | (m) | $5.56M | $0.00 | 14.91× |
| 2024-12-31 | $202.13M | $14.72M | $15.13M | (m) | (m) | (m) | $4.54M | (m) | 13.73× |
| 2024-09-30 | $226.40M | $12.79M | $21.43M | (m) | (m) | (m) | $4.61M | (m) | 17.70× |
| 2024-06-30 | $127.69M | $11.29M | $23.86M | (m) | (m) | (m) | $3.39M | (m) | 11.31× |
| 2024-03-31 | $146.19M | $9.81M | $16.79M | (m) | (m) | (m) | $2.85M | (m) | 14.90× |
| 2023-12-31 | $165.95M | $10.60M | $26.59M | (m) | (m) | (m) | $3.50M | (m) | 15.66× |
| 2023-09-30 | $170.10M | $8.96M | $27.69M | (m) | (m) | (m) | $3.22M | (m) | 18.98× |
| 2023-06-30 | $107.90M | $5.88M | $22.75M | (m) | (m) | (m) | $2.50M | (m) | 18.33× |
| 2023-03-31 | $117.63M | $4.92M | $33.98M | (m) | (m) | (m) | $1.57M | (m) | 23.90× |
| 2022-12-31 | $128.95M | $5.87M | $52.10M | (m) | (m) | (m) | $1.33M | (m) | 21.98× |
| 2022-09-30 | $137.07M | $5.16M | $119.84M | (m) | (m) | (m) | $893.00K | (m) | 26.55× |
| 2022-06-30 | $145.38M | $3.71M | $95.15M | (m) | (m) | (m) | $805.00K | (m) | 39.23× |
| 2022-03-31 | $154.54M | $16.32M | $79.23M | (m) | (m) | (m) | $1.30M | $12.50M | 9.47× |
| 2021-12-31 | $165.00M | $14.66M | $34.01M | (m) | (m) | (m) | $1.44M | $8.33M | 11.26× |
| 2021-09-30 | $174.58M | $10.66M | $44.70M | (m) | (m) | (m) | $1.28M | $4.17M | 16.38× |
| 2021-06-30 | $183.49M | $5.63M | $40.65M | (m) | (m) | (m) | $2.14M | (m) | 32.56× |
| 2021-03-31 | $194.80M | $7.21M | $55.98M | (m) | (m) | (m) | $2.72M | (m) | 27.03× |
| 2020-12-31 | $85.12M | $8.17M | $22.88M | (m) | (m) | (m) | $2.60M | (m) | 10.41× |
| 2020-09-30 | $96.33M | $7.64M | $35.22M | (m) | (m) | (m) | $1.75M | (m) | 12.61× |
| 2020-06-30 | $102.56M | $6.45M | $47.12M | (m) | (m) | (m) | $2.01M | (m) | 15.89× |
| 2020-03-31 | $107.44M | $7.73M | $34.52M | (m) | (m) | (m) | $1.23M | (m) | 13.90× |
| 2019-12-31 | $124.07M | $10.88M | $49.80M | (m) | (m) | (m) | $3.41M | (m) | 11.40× |
| 2019-09-30 | $108.35M | $8.29M | $17.79M | (m) | (m) | (m) | $2.90M | (m) | 13.07× |
| 2019-06-30 | $114.17M | $9.05M | $16.83M | (m) | (m) | (m) | $4.44M | (m) | 12.61× |
| 2019-03-31 | $107.52M | $8.92M | $25.67M | (m) | (m) | (m) | $3.50M | (m) | 12.05× |
| 2018-12-31 | $113.34M | $7.25M | $24.30M | (m) | (m) | (m) | $3.88M | (m) | 15.63× |
| 2018-09-30 | $114.75M | $11.22M | $24.95M | (m) | (m) | (m) | $3.24M | (m) | 10.23× |
| 2018-06-30 | $77.44M | $7.52M | $23.60M | (m) | (m) | (m) | $2.52M | (m) | 10.30× |
| 2018-03-31 | $87.57M | $5.39M | $22.12M | (m) | (m) | (m) | $3.42M | (m) | 16.26× |
| 2017-12-31 | $97.86M | $6.01M | $22.12M | (m) | (m) | (m) | $2.78M | (m) | 16.27× |
| 2017-09-30 | $55.52M | $6.08M | $19.81M | (m) | (m) | (m) | $1.67M | (m) | 9.14× |
| 2017-06-30 | $63.67M | $8.14M | $61.13M | (m) | (m) | (m) | $1.93M | (m) | 7.82× |
| 2017-03-31 | $8.16M | $6.59M | $7.77M | (m) | (m) | (m) | $502.00K | (m) | 1.24× |
| 2016-12-31 | $14.61M | $3.46M | $13.37M | (m) | (m) | (m) | $536.00K | (m) | 4.23× |
| 2016-09-30 | $28.28M | $20.89M | $20.52M | (m) | (m) | (m) | $1.50M | (m) | 1.35× |
| 2016-06-30 | $35.82M | $25.36M | $24.49M | (m) | (m) | (m) | $2.30M | (m) | 1.41× |
| 2016-03-31 | $38.25M | $22.67M | $23.52M | (m) | (m) | (m) | $2.45M | (m) | 1.69× |
| 2015-12-31 | $42.25M | $23.17M | $23.05M | (m) | (m) | (m) | $2.60M | (m) | 1.82× |
| 2015-09-30 | $51.45M | $13.52M | $32.21M | (m) | (m) | (m) | $2.93M | (m) | 3.81× |
| 2015-06-30 | $44.75M | $10.80M | $21.21M | (m) | (m) | (m) | $2.00M | (m) | 4.14× |
| 2015-03-31 | $50.56M | $9.18M | $27.93M | (m) | (m) | (m) | $2.28M | (m) | 5.51× |
| 2014-12-31 | $58.40M | $8.44M | $35.81M | (m) | (m) | (m) | $1.37M | (m) | 6.92× |
| 2014-09-30 | $44.06M | $7.51M | $25.98M | (m) | (m) | (m) | $1.15M | (m) | 5.87× |
| 2014-06-30 | $47.56M | $5.75M | $26.37M | (m) | (m) | (m) | $1.23M | (m) | 8.28× |
| 2014-03-31 | $50.61M | $6.17M | $29.85M | (m) | (m) | (m) | $1.45M | (m) | 8.21× |
| 2013-12-31 | $45.53M | $4.83M | $25.68M | (m) | (m) | (m) | $964.00K | (m) | 9.42× |
| 2013-09-30 | $49.93M | $3.98M | $30.23M | (m) | (m) | (m) | $794.67K | (m) | 12.56× |
| 2013-06-30 | $54.12M | $3.33M | $44.97M | (m) | (m) | (m) | $950.80K | (m) | 16.25× |
| 2013-03-31 | $32.53M | $3.16M | $21.41M | (m) | (m) | (m) | $575.77K | (m) | 10.28× |
| 2012-12-31 | $37.17M | $2.57M | $22.50M | (m) | (m) | (m) | $698.84K | (m) | 14.46× |
| 2012-09-30 | $41.64M | $2.66M | $26.09M | (m) | (m) | (m) | $343.20K | (m) | 15.65× |
| 2012-06-30 | $44.29M | $2.49M | $29.96M | (m) | (m) | (m) | $468.46K | (m) | 17.76× |
| 2012-03-31 | $47.31M | $1.95M | $35.05M | (m) | (m) | (m) | $316.71K | (m) | 24.32× |
| 2011-12-31 | $51.79M | $2.47M | $43.57M | (m) | (m) | (m) | $451.70K | (m) | 20.98× |
| 2011-09-30 | $39.04M | $3.12M | $32.77M | (m) | (m) | (m) | $489.20K | (m) | 12.50× |
| 2011-06-30 | $42.73M | $2.36M | $41.96M | (m) | (m) | (m) | $872.49K | (m) | 18.08× |
| 2010-12-31 | $28.41M | $1.80M | $27.98M | (m) | (m) | (m) | $479.78K | (m) | 15.77× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |